The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Guseva S.D.

Dermatovenerological Dispensary #16, Moscow

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

The role of the vascular factors in the development and progression of scleroderma (international literature review)

Authors:

Korsunskaia I.M., Guseva S.D., Nevozinskaia Z.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2017;16(6): 23‑31

DOI: 10.17116/klinderma201716623-30

Views: 3462

Downloaded: 95

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF THE VASCULAR FACTORS IN THE DEVELOPMENT AND PROGRESSION OF SCLERODERMA (INTERNATIONAL LITERATURE REVIEW)
THE ROLE OF THE VASCULAR FACTORS IN THE DEVELOPMENT AND PROGRESSION OF SCLERODERMA (INTERNATIONAL LITERATURE REVIEW)

To cite this article:

Korsunskaia IM, Guseva SD, Nevozinskaia ZA. The role of the vascular factors in the development and progression of scleroderma (international literature review). Russian Journal of Clinical Dermatology and Venereology. 2017;16(6):23‑31. (In Russ.)
https://doi.org/10.17116/klinderma201716623-30

 
 
Подписка 2025-2 (Russian Journal of Clinical Dermatology and Venereology)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Endo­thelial cells control vascular growth via regu­lation of Notch signaling pathway in mese­nchymal stro­mal cells. Russian Cardiology Bulletin. 2024;(2):32-38
Predicting the risk of decreased ovarian rese­rve after surgical treatment of patients with deep infi­ltrative endo­metriosis using arti­ficial inte­lligence. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):92-102
Pecu­liarities of angiogenesis in clear cell renal cancer. Russian Journal of Archive of Pathology. 2024;(4):64-70
Effect of pro-inflammatory cyto­kines TNF-a and IL-1b on endo­thelial cells. Russian Cardiology Bulletin. 2024;(4-2):121-127
Gender specificity of angiogenesis in patients with non-muscle inva­sive bladder cancer complicated by type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2025;(3):73-79

Scleroderma is a connective tissue disease characterized by involvement of small and large blood vessels, inflammation, autoimmune and tissue reconstruction, which often leads to scarring and fibrosis in the blood vessels and internal organs. As can be seen from the definition, vascular disorders play an important, if not crucial, role in the development of scleroderma. The article presents the literature review and analyzes the role of microcirculation disorders in the development and progression of scleroderma.

Keywords:

scleroderma
angiogenesis
pro-angiogenic factors
anti-angiogenic factors

Authors:

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Guseva S.D.

Dermatovenerological Dispensary #16, Moscow

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

List of references:

  1. Kahaleh B. The microvascular endothelium in scleroderma. Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v14-v15.
  2. Gomer RH. Circulating progenitor cells and scleroderma. Curr Rheumatol Rep. 2008 Jul;10(3):183-188.
  3. Ludwig RJ, Werner RJ, Winker W, et al. Chronic venous insufficiency — a potential trigger for localized scleroderma. J Eur Acad Dermatol Venereol. 2006 Jan;20(1):96-99.
  4. Hummers LK. Biomarkers of vascular disease in scleroderma. Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v21-v22.
  5. Liakouli V, Cipriani P, Marrelli A, et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev. 2011 Aug;10(10):590-594. Epub 2011 Apr 28. https://doi.org/10.1016/j.autrev.2011.04.019
  6. Sigal LH. Transforming growth factor-β. J Clin Rheumatol. 2012 Aug;18(5):268-272. Basic Science for the Clinician 57.
  7. Maring JA, Trojanowska M, ten Dijke P. Role of endoglin in fibrosis and scleroderma. Int Rev Cell Mol Biol. 2012;297:295-308.
  8. Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther. 2012 Jun 13;14(3):R144.
  9. Veraldi KL, Feghali-Bostwick CA. Insulin-like growth factor binding proteins-3 and -5: central mediators of fibrosis and promising new therapeutic targets. Open Rheumatol J. 2012;6:140-145. Epub 2012 Jun 15
  10. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol. 2008 Dec;35(12):2363-2371. Epub 2008 Nov 1. https://doi.org/10.3899/jrheum.080340
  11. Hsu E, Feghali-Bostwick CA. Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. Am J Pathol. 2008 Jun;172(6):1580-1590. Epub 2008 May 8. https://doi.org/10.2353/ajpath.2008.071021
  12. Fawzi MM, Tawfik SO, Eissa AM, et al. Expression of insulin-like growth factor-I in lesional and non-lesional skin of patients with morphoea. Br J Dermatol. 2008 Jul;159(1):86-90. Epub 2008 Jul 1. https://doi.org/10.1111/j.1365-2133.2008.08592.x
  13. Kajihara I, Jinnin M, Honda N, et al. Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor β signaling. Mod Rheumatol. 2012 Jun 28.
  14. Distler K. Hypoxia and angiogenesis in rheumatic diseases. Z Rheumatol. 2003;62(Suppl 2):II43-II45.
  15. Avouac J, Wipff J, Goldman O, et al. Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum. 2008 Nov;58(11):3550-3561.
  16. Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol. 2009 Mar;36(3):576-582. Epub 2009 Feb 17
  17. Shiwen X, Leask A, Abraham DJ, Fonseca C. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma. Eur J Clin Invest. 2009 Jun;39 Suppl 2:19-26.
  18. Slobodin G, Pavlotzky E, Panov J, et al. Endothelin-1 does not change the function of monocyte-derived dendritic cells grown from patients with systemic sclerosis. Immunol Invest. 2008;37(8):841-848.
  19. Soldano S, Montagna P, Villaggio B, et al. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann Rheum Dis. 2009 Apr;68(4):599-602. Epub 2008 Oct 24
  20. Dunne JV, Keen KJ, Van Eeden SF. Circulating angiopoietin and Tie-2 levels in systemic sclerosis. Rheumatol Int. 2013 Feb;33(2):475-484. Epub 2012 Mar 30. https://doi.org/10.1007/s00296-012-2378-4
  21. Peng WJ, Yan JW, Wan YN, et al. Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J Clin Immunol. 2012 Dec;32(6):1409-1414. Epub 2012 Jul 6. https://doi.org/10.1007/s10875-012-9735-7
  22. Margheri F, Serratì S, Lapucci A, et al. Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice. Neoplasia. 2009 Oct;11(10):1106-1115.
  23. Manetti M, Guiducci S, Romano E, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis. 2012 Jun;71(6):1064-1072. Epub 2012 Jan 17. https://doi.org/10.1136/annrheumdis-2011-200837
  24. Asano Y, Ihn H, Jinnin M, et al. Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis. J Dermatol. 2014 Aug;41(8):746-748. Epub 2014 Jul 16. https://doi.org/10.1111/1346-8138.12563
  25. Tamaki Z, Asano Y, Kubo M, et al. Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase-1 genes in scleroderma dermal fibroblasts. J Dermatol Sci. 2014 Jun;74(3):251-259. https://doi.org/10.1016/j.jdermsci.2014.02.002
  26. Frost J, Ramsay M, Mia R, et al. Differential gene expression of MMP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc. Rheumatology (Oxford). 2012 Jun;51(6):1049-1052. Epub 2012 Jan 27. https://doi.org/10.1093/ rheumatology/ker367
  27. Kajihara I, Jinnin M, Makino T, et al. Overexpression of hepatocyte growth factor receptor in scleroderma dermal fibroblasts is caused by autocrine transforming growth factorβ signaling. Biosci Trends. 2012 Jun;6(3):136-412. https://doi.org/10.5582/bst.2012.v6.3.136
  28. Ciechomska M, Huigens CA, Hügle T, et al. Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors. Ann Rheum Dis. 2013 Aug;72(8):1382-1389. Epub 2012 Dec 6. https://doi.org/10.1136/annrheumdis-2012-201958
  29. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm. 2005 Aug 14;2005(3):144-149.
  30. Yamaguchi Y, Feghali-Bostwick CA. Role of endostatin in fibroproliferative disorders.-as a candidate for anti-fibrosis therapy. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(6):452-458.
  31. Farouk HM, Hamza SH, Bakry SA, et al. Dysregulation of angiogenic homeostasis in systemic sclerosis. Int J Rheum Dis. 2013 Aug;16(4):448-454. Epub 2013 Jul 2. https://doi.org/10.1111/1756-185X.12130
  32. Yamaguchi Y, Takihara T, Chambers RA, et al. A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med. 2012 May 30;4(136):136ra71. https://doi.org/10.1126/scitranslmed.3003421
  33. Distler JH, Strapatsas T, Huscher D, et al. Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann Rheum Dis. 2011 Jul;70(7):1197-1202. https://doi.org/10.1136/ard.2010.140657
  34. Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E, et al. Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis—association with pulmonary involvement. Clin Exp Rheumatol. 2006 Sep-Oct;24(5): 508-513.
  35. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4(6):R11. Epub 2002 Aug 30

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.